drugset
drugset / Trial / NCT01363024

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

NCT01363024 ↗

Phase 1 Completed 24 enrolled Genentech, Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.

Timeline

Start
2011-08
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Vofatamab Monoclonal antibody — Intravenous

Indications

neoplasm